4. Discussion
cough, myalgia, lung damage, fatigue
DELETION
In the present study, we investigated the therapeutic role of curcumin nanomicelles as a mediator of inflammatory immune responses in COVID-19 patients. Our study shows that nanocurcumin can be an effective anti-inflammatory drug for treating patients with COVID-19. Nanocurcumin significantly reduced the prevalence of cough, fatigue, and myalgia caused by COVID-19 compared with the control group. Moreover, this supplement reduced oxygen demand and oxygen mask usage. The respiratory rates were significantly declined by nanocurcumin. After two weeks, the oxygen saturation of patients in the treatment group was significantly higher than those in the control group.The COVID-19 pandemic, which emerged in late 2019 and spread worldwide, is still a global concern. Despite many efforts to find a cure, no definite drug or treatment has been found. It is known that the severe form of COVID-19 causing extended lung damage and mortality is a result of cytokine storm and extreme immune response [The anti-inflammatory effects of curcumin have been studied before. Curcumin is one of the most potent anti-inflammatory agents [Curcumin causes this immunomodulation via several mechanisms. It inhibits IKKb activation and increases IKBa production [The application of pure curcumin is not practical and cost-effective because of its rapid metabolism, low bioavailability, weak aqueous solubility, and systemic deletion [Our study faced certain limitations. Firstly, the dropout rate in the curcumin group was relatively high, meaning that factors that prevent adherence to this therapy should be addressed. Secondly, vaccination status was not considered, and the results may not be generalizable to different populations and SARS-CoV-2 strains. However, as over half of Iran's population had received at least one COVID-19 vaccine before the start of the study [